Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
about
Long chain fatty Acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancerChipster: user-friendly analysis software for microarray and other high-throughput dataGREB1 functions as a growth promoter and is modulated by IL6/STAT3 in breast cancerThe prolyl 3-hydroxylases P3H2 and P3H3 are novel targets for epigenetic silencing in breast cancerTargeting androgen receptor in estrogen receptor-negative breast cancerThe transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progressionMicroRNA expression profiling of human breast cancer identifies new markers of tumor subtypeAGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonistResearch advances of arteminPSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancerEfficacy of neoadjuvant Cisplatin in triple-negative breast cancerDiscovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/DoxA gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patientsBiasogram: visualization of confounding technical bias in gene expression dataPredicting response to preoperative chemotherapy agents by identifying drug action on modeled microRNA regulation networks'Omic approaches to preventing or managing metastatic breast cancerA comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression dataSupervised risk predictor of breast cancer based on intrinsic subtypesLeukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapyPhenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancerBreast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications.A systematic evaluation of multi-gene predictors for the pathological response of breast cancer patients to chemotherapy.Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer.Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapyPoint success rate for patient therapeutic response prediction by continuous biomarker scores.Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation.Functional analysis of multiple genomic signatures demonstrates that classification algorithms choose phenotype-related genes.Sequential selection of variables using short permutation procedures and multiple adjustments: An application to genomic data.A new molecular signature method for prediction of driver cancer pathways from transcriptional data.Correction of technical bias in clinical microarray data improves concordance with known biological information.Breast cancer subtype specific classifiers of response to neoadjuvant chemotherapy do not outperform classifiers trained on all subtypesInhibition of proliferation by PERK regulates mammary acinar morphogenesis and tumor formation.Prediction of the outcome of preoperative chemotherapy in breast cancer using DNA probes that provide information on both complete and incomplete responsesKnowledge driven decomposition of tumor expression profilesHypermethylation of genes for diagnosis and risk stratification of prostate cancerEvaluation of microarray preprocessing algorithms based on concordance with RT-PCR in clinical samples.The bimodality index: a criterion for discovering and ranking bimodal signatures from cancer gene expression profiling dataA systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047.Improved microarray-based decision support with graph encoded interactome dataDoes applicability domain exist in microarray-based genomic research?
P2860
Q21132473-DBB68572-C124-4D52-ABC1-27C6D012DFF9Q21267172-470E25BD-8B29-4A7A-85D6-EF579368671AQ21560759-65E14AB4-6638-465A-81F4-2CF01E9B14D1Q24310299-F34693AC-B3D2-46F5-9EDC-82AB2011E2EDQ24312457-287BD3BB-4204-4397-B337-92BA35D85EE3Q24632821-624E663B-90E3-44DC-BD4F-880EC7C587E3Q24646090-6DA6094D-A256-4DC4-8A27-33267CAD86E9Q24652842-5096B96A-28D8-408B-9F8F-790D6C94B87FQ26992299-1A490DDF-CC87-4BEB-8630-F8B205E9F09EQ28267716-06614F52-7F20-46CB-B3F9-2C1A06BBC46AQ28372484-458983B2-23A0-4E3D-9877-117AA1F1A164Q28477021-E3D8BDDE-7005-4DC4-AF85-EC071E68B4F0Q28477202-7A3B0AAB-E257-4DE8-8ACD-3C6DB0B480FCQ28486222-736ABC51-2216-4E9D-9CB9-45678BB12C79Q28539028-80BA1159-02D7-451F-A72F-BE84C746083AQ28730572-0C8C79DC-FEF9-4BB6-9732-82D71555DCE1Q28749765-ADEC50A0-08E0-46FF-8FDA-E11073668492Q29617404-8F581E69-E8E1-4216-B9D5-53C7A52B6D36Q29618033-D0A960FC-A6F6-45F8-9E90-F874F5F088F2Q29619481-BB3E8376-AEC0-4FDF-A4AC-010991F082B5Q30245184-062508AA-A453-46EF-920B-609B11229D8AQ30423830-0CEEF761-D2D7-4CA6-BB60-1F4512769E3EQ30433483-7F35A136-3404-4409-B915-BF68E0C5A524Q30434260-041A30D2-FF13-47C2-BAF0-D72D5B6B660AQ30456795-0EC133C2-9015-45E3-82D5-0864D6DFAC30Q30477571-F3E1D07C-9BD8-48EF-97FD-94E65BDC543FQ30496004-77771F6F-72BF-49ED-90F4-37F3D5E8AE87Q30883810-DEB0660D-A9EE-406C-A5FA-4A8EAA2DED78Q31081853-698571E6-6836-4002-961F-94187C65A1FBQ31145389-45AA2D34-BEEC-4068-B016-2A73BC60278BQ31151786-B0B39280-23FD-4777-BC75-3E6AE0C73608Q33291107-24C152D2-BB21-4EBB-BA73-33F48318AB08Q33325635-8323A75E-282D-46E3-BE8D-74B63759A275Q33407774-05DF1908-D07B-4FF4-B00B-F22FFAD97BC0Q33410858-8E6FA5E3-CED0-4C16-ADC5-2FBE041D6E91Q33450671-683722BD-9A98-470F-B38B-43300FD625C1Q33498527-23AF654F-EDD9-4EF5-9377-BB0C7D220868Q33517982-CB4D6F52-9715-4B9C-A601-FE763788258EQ33564252-3B572991-A553-47C5-835D-D53206A040A8Q33604686-B4E0BA91-CBC4-4684-A989-0D1F5AAC0872
P2860
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Pharmacogenomic predictor of s ...... ophosphamide in breast cancer.
@en
Pharmacogenomic predictor of s ...... ophosphamide in breast cancer.
@nl
type
label
Pharmacogenomic predictor of s ...... ophosphamide in breast cancer.
@en
Pharmacogenomic predictor of s ...... ophosphamide in breast cancer.
@nl
prefLabel
Pharmacogenomic predictor of s ...... ophosphamide in breast cancer.
@en
Pharmacogenomic predictor of s ...... ophosphamide in breast cancer.
@nl
P2093
P356
P1476
Pharmacogenomic predictor of s ...... ophosphamide in breast cancer.
@en
P2093
Aman U Buzdar
Daniel Booser
Gabriel N Hortobagyi
Jaime A Mejia
Jeffrey S Ross
Keith Anderson
Kenneth R Hess
Lajos Pusztai
Nour Sneige
Nuhad Ibrahim
P304
P356
10.1200/JCO.2006.05.6861
P407
P577
2006-08-08T00:00:00Z